QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Tesamorelin?
Tesamorelin is a stabilised full-length GHRH(1-44) analog — the only GHRH analog with FDA approval (Egrifta, 2010) for HIV-associated lipodystrophy. Full GHRH(1-44) sequence provides superior GHRHR binding vs sermorelin (1-29 fragment). Stimulates pulsatile GH release → IGF-1 → visceral fat reduction. Falutz 2010 (NEJM): 15.2% visceral fat reduction vs +5.0% placebo.
Research Applications
Visceral Fat Reduction
15.2% reduction — Falutz 2010 NEJM Phase 3 data
GHRH Analog Comparison
Full-length vs sermorelin (1-29) vs CJC-1295 GH pulse studies
NAFLD/Liver Fat
Stanley 2014: −37% liver fat by MRS — 6 months
IGF-1 Kinetics
Pulsatile GH → hepatic IGF-1 axis — vs direct rhGH
Body Composition
Lean mass preservation, visceral adiposity models
Quick Specs
| Form | Lyophilized powder — 5mg per vial, 10-vial kit |
| CAS Number | 218949-48-5 |
| Molecular Formula | C₂₂₁H₃₆₈N₇₂O₇₀S |
| Molecular Weight | 5135.9 g/mol |
| Compound Type | GHRH(1-44) Analog |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |
